vs
Side-by-side financial comparison of Orion Properties Inc. (ONL) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Orion Properties Inc. is the larger business by last-quarter revenue ($35.2M vs $28.1M, roughly 1.3× ARS Pharmaceuticals, Inc.). Orion Properties Inc. runs the higher net margin — -101.7% vs -147.1%, a 45.5% gap on every dollar of revenue. On growth, Orion Properties Inc. posted the faster year-over-year revenue change (-8.2% vs -67.6%).
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
ONL vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $28.1M |
| Net Profit | $-35.8M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -101.5% | -147.6% |
| Net Margin | -101.7% | -147.1% |
| Revenue YoY | -8.2% | -67.6% |
| Net Profit YoY | -9.3% | -182.8% |
| EPS (diluted) | $-0.63 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $28.1M | ||
| Q3 25 | $37.1M | $32.5M | ||
| Q2 25 | $37.3M | $15.7M | ||
| Q1 25 | $38.0M | $8.0M | ||
| Q4 24 | $38.4M | $86.6M | ||
| Q3 24 | $39.2M | $2.1M | ||
| Q2 24 | $40.1M | $500.0K | ||
| Q1 24 | $47.2M | $0 |
| Q4 25 | $-35.8M | $-41.3M | ||
| Q3 25 | $-69.0M | $-51.2M | ||
| Q2 25 | $-25.1M | $-44.9M | ||
| Q1 25 | $-9.4M | $-33.9M | ||
| Q4 24 | $-32.8M | $49.9M | ||
| Q3 24 | $-10.2M | $-19.1M | ||
| Q2 24 | $-33.8M | $-12.5M | ||
| Q1 24 | $-26.2M | $-10.3M |
| Q4 25 | -101.5% | -147.6% | ||
| Q3 25 | -185.8% | -163.7% | ||
| Q2 25 | -67.1% | -302.9% | ||
| Q1 25 | -24.4% | -466.3% | ||
| Q4 24 | -85.4% | 54.5% | ||
| Q3 24 | -25.9% | -1051.6% | ||
| Q2 24 | -84.1% | -3068.0% | ||
| Q1 24 | -55.4% | — |
| Q4 25 | -101.7% | -147.1% | ||
| Q3 25 | -186.0% | -157.4% | ||
| Q2 25 | -67.3% | -285.6% | ||
| Q1 25 | -24.6% | -425.7% | ||
| Q4 24 | -85.4% | 57.7% | ||
| Q3 24 | -26.1% | -925.0% | ||
| Q2 24 | -84.2% | -2503.2% | ||
| Q1 24 | -55.6% | — |
| Q4 25 | $-0.63 | $-0.41 | ||
| Q3 25 | $-1.23 | $-0.52 | ||
| Q2 25 | $-0.45 | $-0.46 | ||
| Q1 25 | $-0.17 | $-0.35 | ||
| Q4 24 | $-0.59 | $0.52 | ||
| Q3 24 | $-0.18 | $-0.20 | ||
| Q2 24 | $-0.60 | $-0.13 | ||
| Q1 24 | $-0.47 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.4M | $245.0M |
| Total DebtLower is stronger | $465.0M | $96.4M |
| Stockholders' EquityBook value | $623.2M | $114.3M |
| Total Assets | $1.2B | $327.7M |
| Debt / EquityLower = less leverage | 0.75× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.4M | $245.0M | ||
| Q3 25 | $32.6M | $288.2M | ||
| Q2 25 | $17.4M | $240.1M | ||
| Q1 25 | $9.4M | $275.7M | ||
| Q4 24 | $15.6M | $314.0M | ||
| Q3 24 | $16.6M | $204.6M | ||
| Q2 24 | $24.2M | $218.7M | ||
| Q1 24 | $23.6M | $223.6M |
| Q4 25 | $465.0M | $96.4M | ||
| Q3 25 | $483.0M | $96.2M | ||
| Q2 25 | $483.0M | — | ||
| Q1 25 | $505.0M | — | ||
| Q4 24 | $492.0M | $0 | ||
| Q3 24 | $485.0M | — | ||
| Q2 24 | $462.0M | — | ||
| Q1 24 | $471.0M | — |
| Q4 25 | $623.2M | $114.3M | ||
| Q3 25 | $658.8M | $147.7M | ||
| Q2 25 | $728.0M | $192.3M | ||
| Q1 25 | $753.5M | $229.0M | ||
| Q4 24 | $763.9M | $256.8M | ||
| Q3 24 | $800.9M | $201.0M | ||
| Q2 24 | $816.1M | $215.2M | ||
| Q1 24 | $854.6M | $223.9M |
| Q4 25 | $1.2B | $327.7M | ||
| Q3 25 | $1.2B | $372.8M | ||
| Q2 25 | $1.3B | $313.5M | ||
| Q1 25 | $1.3B | $327.3M | ||
| Q4 24 | $1.3B | $351.2M | ||
| Q3 24 | $1.4B | $217.6M | ||
| Q2 24 | $1.3B | $222.0M | ||
| Q1 24 | $1.4B | $227.6M |
| Q4 25 | 0.75× | 0.84× | ||
| Q3 25 | 0.73× | 0.65× | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.64× | 0.00× | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.6M | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $-43.5M | ||
| Q3 25 | $5.7M | $-47.0M | ||
| Q2 25 | $11.6M | $-39.6M | ||
| Q1 25 | $-2.2M | $-40.7M | ||
| Q4 24 | $54.3M | $42.0M | ||
| Q3 24 | $13.8M | $-14.5M | ||
| Q2 24 | $17.0M | $-7.3M | ||
| Q1 24 | $11.0M | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ONL
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
